DelveInsight’s “Behcet’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Behcet’s Disease, historical and forecasted epidemiology as well as the Behcet’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Behcet’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Behcet’s Disease Market Forecast
Some of the key facts of the Behcet’s Disease Market Report:
-
The Behcet’s Disease market size was value ~USD 140 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In March 2025, Christopher J. Schaber, PhD, President and CEO of Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with significant unmet needs, stated that the company remains committed to advancing its diverse clinical pipeline. Key upcoming milestones include the anticipated top-line results in 2026 from the ongoing confirmatory Phase 3 placebo-controlled trial evaluating HyBryte™ (synthetic hypericin) for early-stage cutaneous T-cell lymphoma (CTCL). Additionally, in the latter half of this year, Soligenix expects to announce top-line data from its ongoing Phase 2 trials of SGX945 (dusquetide) for Behçet’s disease and SGX302 (synthetic hypericin) for mild-to-moderate psoriasis.
-
In November 2024, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with unmet medical needs, announced the initiation of patient enrollment for its Phase 2 clinical trial (protocol number DUS-AUBD-01) assessing SGX945 (dusquetide) as a treatment for Behçet's Disease.
-
Among the EU4 and the UK, Italy has the largest market size at around USD 10 million, followed by France with approximately USD 8 million. These figures are anticipated to change over the forecast period (2024-2034) due to ongoing research and development efforts, which may result in the discovery of more effective treatments for Behcet’s Syndrome.
-
In January 2024, Soligenix announced that the US Food and Drug Administration (FDA) has granted fast track designation to SGX945 (dusquetide)
-
In 2023, Japan had the highest number of diagnosed prevalent cases of Behcet’s syndrome among the 7MM countries.
-
In 2023, Italy had the highest number of diagnosed prevalent cases among the EU4 and the UK, with approximately 7,000 cases. This number is expected to increase by 2034.
-
In 2023, the total diagnosed prevalent cases of Behcet's Syndrome in the US were approximately 3,500 for pediatric patients and around 16,000 for young adults.
-
Among the clinical manifestations of Behcet's Syndrome in the US, oral ulcers were the most prevalent, representing about 30% of the total cases, followed by genital ulcers.
-
In the EU4 countries and the UK, oral ulcers were the most common, with approximately 5,000 cases, followed by genital ulcers, which accounted for around 3,000 cases.
-
Key Behcet’s Disease Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others
-
Key Behcet’s Disease Therapies: SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others
-
The Behcet’s Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Behcet’s Disease pipeline products will significantly revolutionize the Behcet’s Disease market dynamics.
Behcet’s Disease Overview
Behcet's Disease is a rare, chronic, and multisystem inflammatory disorder characterized by recurring episodes of inflammation affecting various parts of the body. It is named after the Turkish dermatologist Hulusi Behçet, who first described the condition in 1937. The disease primarily affects blood vessels, causing symptoms that can involve the mouth, eyes, skin, joints, and other organs.
Get a Free sample for the Behcet’s Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/behcets-disease-market
Behcet’s Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Behcet’s Disease Epidemiology Segmentation:
The Behcet’s Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Diagnosed Prevalent Cases of Behcet's Syndrome in the 7MM
-
Diagnosed Cases of Behcet’s Syndrome Based on the Age of Onset in the 7MM
-
Clinical Manifestations Associated With Behcet’s Syndrome in the 7MM
-
Total Patients Seeking Treatment for Behcet's Syndrome in the 7MM
Download the report to understand which factors are driving Behcet’s Disease epidemiology trends @ Behcet’s Disease Epidemiology Forecast
Behcet’s Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Behcet’s Disease market or expected to get launched during the study period. The analysis covers Behcet’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Behcet’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Behcet’s Disease Therapies and Key Companies
-
SGX945: Soligenix
-
RAY121: Chugai Pharmaceutical
-
Dusquetide: Soligenix
-
Filgotinib: UMC Utrecht
-
Hemay005: Ganzhou Hemay Pharmaceutical
-
Apremilast: Amgen
Discover more about therapies set to grab major Behcet’s Disease market share @ Behcet’s Disease Treatment Landscape
Behcet’s Disease Market Strengths
-
The constant efforts by researchers to determine clear molecular pathogenesis are progressively increasing.
-
Studies suggest that Behcet’s syndrome shares common features with autoimmune and inflammatory disorders, thus leading to the detection of the main mediators involved in the pathomechanism of Behcet’s syndrome.
Behcet’s Disease Market Opportunities
-
There is an attractive market for therapies with a primary goal of treatment to rapidly suppress and prevent new inflammatory attacks to avoid irreversible organ damage, especially in the early, active stages of Behcet’s syndrome.
-
As a consequence of escalating knowledge and awareness among providers and caregivers about Behcet’s syndrome, the prevalence of the disease is increasing, which may further expedite the R&D.
Scope of the Behcet’s Disease Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Behcet’s Disease Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others
-
Key Behcet’s Disease Therapies: SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others
-
Behcet’s Disease Therapeutic Assessment: Behcet’s Disease current marketed and Behcet’s Disease emerging therapies
-
Behcet’s Disease Market Dynamics: Behcet’s Disease market drivers and Behcet’s Disease market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Behcet’s Disease Unmet Needs, KOL’s views, Analyst’s views, Behcet’s Disease Market Access and Reimbursement
To know more about Behcet’s Disease companies working in the treatment market, visit @ Behcet’s Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Behcet’s Disease Market Report Introduction
2. Executive Summary for Behcet’s Disease
3. SWOT analysis of Behcet’s Disease
4. Behcet’s Disease Patient Share (%) Overview at a Glance
5. Behcet’s Disease Market Overview at a Glance
6. Behcet’s Disease Disease Background and Overview
7. Behcet’s Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Behcet’s Disease
9. Behcet’s Disease Current Treatment and Medical Practices
10. Behcet’s Disease Unmet Needs
11. Behcet’s Disease Emerging Therapies
12. Behcet’s Disease Market Outlook
13. Country-Wise Behcet’s Disease Market Analysis (2020–2034)
14. Behcet’s Disease Market Access and Reimbursement of Therapies
15. Behcet’s Disease Market Drivers
16. Behcet’s Disease Market Barriers
17. Behcet’s Disease Appendix
18. Behcet’s Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
